The estimated Net Worth of Joydeep Goswami is at least $3.52 Million dollars as of 21 February 2023. Mr. Goswami owns over 4,696 units of Illumina Inc stock worth over $1,534,410 and over the last 5 years he sold ILMN stock worth over $0. In addition, he makes $1,984,820 as Senior Vice President - Corporate Development and Strategic Planning at Illumina Inc.
Joydeep has made over 2 trades of the Illumina Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 4,696 units of ILMN stock worth $586,202 on 21 February 2023.
The largest trade he's ever made was exercising 4,696 units of Illumina Inc stock on 21 February 2023 worth over $586,202. On average, Joydeep trades about 347 units every 15 days since 2019. As of 21 February 2023 he still owns at least 12,292 units of Illumina Inc stock.
You can see the complete history of Mr. Goswami stock trades at the bottom of the page.
Joydeep Goswami is Senior Vice President - Corporate Development and Strategic Planning of the Company. With more than 20 years of global experience, Mr. Goswami has a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions. Most recently, he served as the President of Thermo Fisher Scientific's Clinical Next-Generation Sequencing (NGS) and Oncology business unit, where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health.
As the Senior Vice President - Corporate Development and Strategic Planning of Illumina Inc, the total compensation of Joydeep Goswami at Illumina Inc is $1,984,820. There are 3 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
Joydeep's mailing address filed with the SEC is 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL, WA, 98021.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley, and Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: